Goldman Sachs analysts removed Fresenius Medical (FMS) Care from the firm’s European Conviction List as part of its monthly update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 60 from EUR 55 at Berenberg
- Fresenius Medical Care: Hold Rating Amid Ambitious Targets and Execution Risks
- Fresenius Medical Care Launches EUR 1 Billion Share Buyback Program
- Fresenius Medical launches its new FME Reignite strategy
- Fresenius Medical price target raised to EUR 52.50 from EUR 46.50 at Citi